DK2491946T3 - Adjuvans til vacciner - Google Patents
Adjuvans til vacciner Download PDFInfo
- Publication number
- DK2491946T3 DK2491946T3 DK10824502.8T DK10824502T DK2491946T3 DK 2491946 T3 DK2491946 T3 DK 2491946T3 DK 10824502 T DK10824502 T DK 10824502T DK 2491946 T3 DK2491946 T3 DK 2491946T3
- Authority
- DK
- Denmark
- Prior art keywords
- ova
- adjuvant
- cells
- omp19s
- immunized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/23—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Brucella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Claims (9)
1. Adjuvans til vacciner, kendetegnet ved, at adjuvansen omfatter et ikke-lipideret bakterielt ydre membranpolypeptid (Omp) fra slægten Brucella, valgt blandt ikke-lipideret Ompl9S polypeptid og ikke-lipideret Ompl6S polypeptid.
2. Adjuvans ifølge krav 1, kendetegnet ved, at det ikke-lipiderede polypeptid omfatter SEQ ID NO: 1.
3. Adjuvans ifølge krav 1 , kendetegnet ved, at det ikke-lipiderede polypeptid omfatter SEQ ID NO: 2.
4. En vaccine, kendetegnet ved, at den omfatter en adjuvans ifølge ethvert af kravene 1 til 3. og mindst et antigen.
5. Vaccinen ifølge krav 4, kendetegnet ved, at vaccinen er en vaccine valgt fra gruppen bestående af mucosal og parenterale vacciner.
6. Adjuvans ifølge krav 1 til anvendelse som adjuvans til vacciner mod et patogen.
7. Adjuvans ifølge krav 6, hvor patogenet har mindst en intracellulær fase i dets livscyklus.
8. Adjuvans ifølge krav 6 , hvor vaccinen er et antitumor vaccine.
9. Adjuvans ifølge krav 1 til anvendelse som adjuvans i et immunomodulerende præparat.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP090104015A AR073907A1 (es) | 2009-10-19 | 2009-10-19 | Adyuvante para vacunas, que comprende un polipeptido no lipidado de la membrana externa (omp) de bacterias, vacunas que lo comprenden y usos |
| PCT/ES2010/070667 WO2011048248A1 (es) | 2009-10-19 | 2010-10-18 | Adyuvante para vacunas, vacunas que lo comprenden y usos. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2491946T3 true DK2491946T3 (da) | 2015-07-27 |
Family
ID=43566830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10824502.8T DK2491946T3 (da) | 2009-10-19 | 2010-10-18 | Adjuvans til vacciner |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9511137B2 (da) |
| EP (1) | EP2491946B1 (da) |
| CN (1) | CN102711815B (da) |
| AR (1) | AR073907A1 (da) |
| BR (1) | BR112012009239B1 (da) |
| CA (1) | CA2778359C (da) |
| DK (1) | DK2491946T3 (da) |
| ES (1) | ES2542973T3 (da) |
| MX (1) | MX2012004622A (da) |
| WO (1) | WO2011048248A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106117365B (zh) * | 2016-06-23 | 2018-07-27 | 湖南农业大学 | 抗猪链球菌病且具有自身免疫活性的融合蛋白及其制备和应用 |
| CN106188307B (zh) * | 2016-07-06 | 2019-01-04 | 长沙爱科博生物科技有限公司 | 一种融合蛋白、其制备方法及一种猪用口服疫苗或药物 |
| CN107375922B (zh) * | 2017-07-20 | 2020-06-09 | 南京农业大学 | 一种水溶性复合免疫佐剂及猪圆环病毒病疫苗 |
| WO2019155415A1 (en) * | 2018-02-09 | 2019-08-15 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) | Immunomodulating and immunostimulating polypeptides for drug-delivery |
| CN109486846B (zh) * | 2018-12-29 | 2021-08-20 | 山东农业大学 | 一种布鲁氏菌三种基因重组质粒、构建方法及其在大肠杆菌中的表达和应用 |
| CN114073762B (zh) * | 2020-08-12 | 2023-07-21 | 中国人民解放军军事科学院军事医学研究院 | 一种含有Omp19和VirB8蛋白的布鲁氏菌病双组分疫苗 |
| CN115267204A (zh) * | 2022-08-02 | 2022-11-01 | 中国农业科学院北京畜牧兽医研究所 | 一种评估羊群是否免疫布鲁氏菌病疫苗的方法及试剂盒 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2816844A1 (fr) * | 2000-11-17 | 2002-05-24 | Pf Medicament | Domaine periplasmique d'une proteine omp d'enterobacterie et son utilisation comme porteur et/ou adjuvant |
| ES2190350B1 (es) * | 2001-07-31 | 2005-01-01 | Jose Instituto Cientifico Y Tecnologico De Navarra, S.A(67%) | Composicion de vacuna frente a la brucelosis que comprende microparticulas de poli (e-caprolactona) como adyuvante. |
-
2009
- 2009-10-19 AR ARP090104015A patent/AR073907A1/es not_active Application Discontinuation
-
2010
- 2010-10-18 US US13/502,721 patent/US9511137B2/en active Active
- 2010-10-18 ES ES10824502.8T patent/ES2542973T3/es active Active
- 2010-10-18 CA CA2778359A patent/CA2778359C/en active Active
- 2010-10-18 EP EP10824502.8A patent/EP2491946B1/en active Active
- 2010-10-18 DK DK10824502.8T patent/DK2491946T3/da active
- 2010-10-18 MX MX2012004622A patent/MX2012004622A/es unknown
- 2010-10-18 WO PCT/ES2010/070667 patent/WO2011048248A1/es active Application Filing
- 2010-10-18 BR BR112012009239-1A patent/BR112012009239B1/pt active IP Right Grant
- 2010-10-18 CN CN201080057967.3A patent/CN102711815B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2542973T3 (es) | 2015-08-13 |
| BR112012009239B1 (pt) | 2021-10-13 |
| BR112012009239A2 (pt) | 2017-06-06 |
| US20120258145A1 (en) | 2012-10-11 |
| WO2011048248A1 (es) | 2011-04-28 |
| EP2491946A4 (en) | 2013-06-19 |
| AR073907A1 (es) | 2010-12-09 |
| CA2778359C (en) | 2019-07-16 |
| MX2012004622A (es) | 2012-05-08 |
| CN102711815A (zh) | 2012-10-03 |
| EP2491946A1 (en) | 2012-08-29 |
| EP2491946B1 (en) | 2015-04-22 |
| CN102711815B (zh) | 2015-05-20 |
| CA2778359A1 (en) | 2011-04-28 |
| US9511137B2 (en) | 2016-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2491946T3 (da) | Adjuvans til vacciner | |
| JP6041851B2 (ja) | フラジェリンに基づく新規の免疫アジュバント化合物及びその使用 | |
| JP7095053B2 (ja) | 免疫原性化合物 | |
| US7635479B2 (en) | Composition and methods for enhancing immunogenecity of antigens | |
| US20020025323A1 (en) | Compositions and methods for enhancing immunogenicity of antigens | |
| EP2478915A1 (en) | CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses | |
| EP2968423A1 (en) | Compositions and methods of enhancing immune responses to enteric pathogens | |
| Kabiri et al. | The novel immunogenic chimeric peptide vaccine to elicit potent cellular and mucosal immune responses against HTLV-1 | |
| US9023363B2 (en) | A1 moiety of cholera toxin A subunit as an adjuvant for mucosal and systemic vaccines | |
| Goldoni et al. | Mucosal and systemic anti-GAG immunity induced by neonatal immunization with HIV LAMP/gag DNA vaccine in mice | |
| US9119803B2 (en) | Carious tooth vaccine and preparation method | |
| US20100136058A1 (en) | DNA vaccines against tumor growth and methods of use thereof | |
| US20220332770A1 (en) | High-Density Flagellin-Displaying Virus-Like Particle As Vaccine Carrier | |
| Neeli et al. | Comparison of DNA vaccines with AS03 as an adjuvant and an mRNA vaccine against SARS-CoV-2 | |
| US20220378892A1 (en) | Recombinant expression of chlamydia momp antigen | |
| WO2011033319A1 (en) | Commensal neisserial stress protein preparations | |
| WO2017184456A1 (en) | Toxoplasma gondii vaccines and their use | |
| AU2014200430A1 (en) | Novel immunoadjuvant compounds and use thereof |